Medical Devices · New York, New York, United States
$0.97
+0.00% (+$0.00)2026-07-09
Smart-Money SignalNeutral · 51/100— Insiders are net buyers over 90 days ($245K, 1 buy vs 0 sales)
Revenue$1.3M
Net Income-$13.9M
EPS$-0.59
Market Cap$159.9M
Price Performance
Historical data including institutional events
Company Profile
L
Lishan Aklog
CEO & Executive Director
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
The companyâs flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
